- Home
- ESPR vs POLE Comparison
ESPR vs POLE Comparison
Compare ESPR & POLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- POLE
- Stock Information
- Founded
- ESPR 2008
- POLE 2024
- Country
- ESPR United States
- POLE United States
- Employees
- ESPR N/A
- POLE N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- POLE
- Sector
- ESPR Health Care
- POLE
- Exchange
- ESPR Nasdaq
- POLE NYSE
- Market Cap
- ESPR 305.0M
- POLE 299.8M
- IPO Year
- ESPR 2013
- POLE 2024
- Fundamental
- Price
- ESPR $0.80
- POLE $10.26
- Analyst Decision
- ESPR Buy
- POLE
- Analyst Count
- ESPR 7
- POLE 0
- Target Price
- ESPR $5.93
- POLE N/A
- AVG Volume (30 Days)
- ESPR 5.1M
- POLE 87.7K
- Earning Date
- ESPR 05-06-2025
- POLE 01-01-0001
- Dividend Yield
- ESPR N/A
- POLE N/A
- EPS Growth
- ESPR N/A
- POLE N/A
- EPS
- ESPR N/A
- POLE N/A
- Revenue
- ESPR $259,574,000.00
- POLE N/A
- Revenue This Year
- ESPR $5.70
- POLE N/A
- Revenue Next Year
- ESPR N/A
- POLE N/A
- P/E Ratio
- ESPR N/A
- POLE $57.91
- Revenue Growth
- ESPR 12.99
- POLE N/A
- 52 Week Low
- ESPR $0.82
- POLE $9.94
- 52 Week High
- ESPR $3.94
- POLE $11.16
- Technical
- Relative Strength Index (RSI)
- ESPR 32.43
- POLE N/A
- Support Level
- ESPR $0.93
- POLE N/A
- Resistance Level
- ESPR $1.11
- POLE N/A
- Average True Range (ATR)
- ESPR 0.11
- POLE 0.00
- MACD
- ESPR 0.01
- POLE 0.00
- Stochastic Oscillator
- ESPR 17.93
- POLE 0.00
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About POLE ANDRETTI ACQUISITION CORP. II
Andretti Acquisition Corp II is a blank check company.